Research programme: tau protein targeting therapeutics - Cantabio Pharmaceuticals/University of Cambridge

Drug Profile

Research programme: tau protein targeting therapeutics - Cantabio Pharmaceuticals/University of Cambridge

Alternative Names: CB 401; Chaperone-based therapeutics - Cantabio Pharmaceuticals/University of Cambridge; Tau protein modulators - Cantabio Pharmaceuticals/University of Cambridge

Latest Information Update: 21 Sep 2016

Price : $50

At a glance

  • Originator Elan Pharmaceuticals; Max Planck Research Unit for Structural Molecular Biology; NovALiX; University of Cambridge
  • Developer Cantabio Pharmaceuticals; Elan Pharmaceuticals; Max Planck Research Unit for Structural Molecular Biology; NovALiX; University of Cambridge
  • Class Antidementias; Small molecules
  • Mechanism of Action Tau protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Dementia

Most Recent Events

  • 07 Sep 2016 Tau protein targeting therapeutics licensed to Cantabio Pharmaceuticals worldwide for the treatment of Alzheimer's disease and Demntia
  • 07 Sep 2016 Preclinical trials of CB 401 in Alzheimer's disease in USA (unspecified route) (Cantabio pipeline, September 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top